



ASX ANNOUNCEMENT

H1 FY2026 Financial Results

Strong Revenue Growth, Improving Clinics Performance, Nicotine Vaping Product Growth and OPEX Reduction.

Focus on Accelerated Execution and Improved Financial Results.

25 FEBRUARY 2026

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**), a leading digital health business, today released its financial results for the half-year ended 31 December 2025 (**H1 FY2026**).

Key Highlights

- Total revenue of \$67.9 Million (PCP \$62.7 Million) – up 8.3%.
- Normalised EBITDA (nEBITDA) of \$1.9 Million - down from \$4.6 Million vs PCP. December 2025 nEBITDA encouraging, with momentum building for H2 FY2026.
- Normalised loss after income tax (NPAT) of (\$0.4 Million) – vs PCP profit \$2.2 Million (-118%), driven largely by sector-wide compression of medicinal cannabis pricing and increased doctor costs. Consolidated loss after income tax for the period of \$1.0 Million.
- Leadership transition in place to drive accelerated execution and improved financial results in H2 FY2026 and beyond.
- Management restructure and total operational expenditure reduced by 10%, delivering annualised run-rate savings of \$2.8 Million going forward.
- Doctors on Demand (**DoD**) telehealth business continued strong growth - 21% growth in revenue vs PCP.
- Nicotine Vaping Product (NVP) growth exceeding forecast with a six-month average growth rate above 16%, with expansion plans in place.
- Candor integration maturing, with CDA Clinics and Cannadoc now migrated onto the same platform, providing a more seamless and consistent patient experience across all clinics – now known as Vitura’s ‘Specialty Clinics’ division.
- Releaf continues to expand, increasing consultation numbers and additional product sales via Canview.
- Creation of new Industry Advisory Group.
- Overall outlook expected to see continuation of revenue growth and focus on restoring nEBITDA growth in H2 FY2026.

Results Summary

A\$ Million	H1 FY2026	H1 FY2025
Operating revenue	67.9	62.7
Normalised EBITDA ^(note)	1.9	4.6
Net profit after tax (NPAT)	(1.0)	1.6
Normalised NPAT ^(note)	(0.4)	2.2
Normalised earnings per share (EPS) (cents)	(0.05)	0.37

Note: Normalised for costs relating to acquisitions and the successful resolution of legal disputes.

Financial and Operational Overview

The Company's revenue for H1 FY2026 was \$67.9 Million, an increase of 8.3% over H1 FY2025. This was driven from the sale and distribution of medicinal cannabis and other items - eg Nicotine Vaping Products - (\$52.0 Million – up 4%) and rising digital medical consultation and service fees (\$15.9 Million – up 25%).

Vitura's wholly-owned subsidiary, Burleigh Heads Cannabis Pty Ltd ("BHC"), sold a total of 507,799 units of medicinal cannabis via its Canview platform – 10.6% up versus the previous corresponding period.

The total number of Australian pharmacies with established accounts on Vitura's Canview platform now represents more than 4 in 5 of all pharmacies in the country actively dispensing medicinal cannabis.

Performance in the NVP market exceeded revenue expectations for the first half, with an encouraging six-month average growth rate above 16%, and NVPs recording its first million-dollar revenue month during the first half. Continued NVP sales growth remains a focus for the Company into H2 FY2026 and beyond.

Despite top line growth in H1 FY2026, price and margin compression across the competitive medicinal cannabis sector held nEBITDA to \$1.9 Million. The Company generated a consolidated loss after income tax for the period of \$1.0 Million.

However, the Company has clear plans to stabilise margins, further improve clinic performance, reduce operational expenditure and drive other revenue streams in H2 FY2026 and beyond.

To drive the focus on accelerated execution and improved financial results, Vitura announced a leadership transition in January 2026. Chief Revenue Officer Ryan Tattle assumed responsibility for day-to-day management while Non-Executive Director Shane Tanner assumed an Interim Executive Director role to provide extra support and focus. New CFO Andrew Cook commenced on 9 February 2026, earlier than expected, and a new CEO search is well underway.

Management restructuring and total operational expenditure has already been reduced by 10%, immediately delivering annualised run-rate savings of \$2.8 Million.

Doctors on Demand (DoD)

Vitura's **Doctors on Demand (DoD)** virtual GP primary care telehealth service continued its strong growth, delivering another record number of patient consultations in the period.

DoD experienced 21% growth in revenue, compared to the previous corresponding period. Total consultation numbers increased by 15% year-on-year. Daily consultation numbers consistently exceeded expectations with a shift in the demand for afterhours consultations, which increased by almost 32%, driven mainly by B2C patients.

DoD's B2B business remains a priority, with the business continuing to explore further employee group opportunities in H2 FY2026.

Candor, CDA Clinics and Cannadoc – Specialty Clinics Division

The integration of **Candor Medical** continues to add value to the Company, bringing access to an additional 15,000 active patients through its modern and fully integrated digital platform. Acquired in February 2025, Candor's platform has become the centrepiece of Vitura's new 'Specialty Clinics' division - with **CDA** and **Cannadoc** now migrated onto the same platform to provide a more seamless and consistent patient experience across all clinics.

Vitura's Specialty Clinics division enters H2 FY2026 with improved platform capability, strengthened clinical leadership and clear priorities to support scaling and sustainable growth. This will be strengthened by increased digital spend, doctor recruitment, retention and availability, and the launch of a NVP service via Candor.

A planned product expansion for Adaya and Inscape SKUs – Vitura owned products – should deliver higher overall margins.

Relief Group ("Relief")

The Company's JV with Flora Holdings Pty Ltd (Flora) to acquire the major assets of **Relief** in November 2024, is seeing a return to base patient volumes through its mix of telehealth and in-person clinics.

Re-engagement of Relief's 30,000 patient base and recruitment of new doctors and staff meant Relief continued to expand, driving increases in consultation numbers and additional product sales via Canview.

Corporate Update

On 18 December 2025, the Company announced the appointment of Michael Sapountzis as Company Secretary. Mr Sapountzis has more than 12 years' professional experience, providing company secretarial, governance and compliance support to Boards across a range of industries and sectors, including ASX-listed companies. He holds a Bachelor of Commerce and Bachelor of Laws, is a Graduate of the Australian Institute of Company Directors and is a Fellow of the Governance Institute of Australia.

On 9 January 2026, the Company announced experienced finance executive Andrew Cook as its new Chief Financial Officer. Mr Cook has over 20 years' international experience in senior finance roles across diverse industries with a strong track record of delivery in large complex organisations. He has held senior positions in leading businesses including Energy Queensland, Origin Energy, SABMiller and most recently as Chief Financial Officer and Company Secretary of AnteoTech Limited. Mr Cook commenced at Vitura in the role on 9 February 2026, ahead of expectations.

On 29 January 2026, the Company announced a CEO transition and interim leadership update, including that Chief Executive Officer, Geoff Cockerill, had ceased his role on 28 January 2026. Vitura's Chief Revenue Officer, Ryan Tattle, has assumed expanded leadership responsibility for the Company's day-to-day management, until a new CEO is appointed. To support the executive team, Shane Tanner, previously a Non-Executive Director, stepped into an Interim Executive Director role with the Company's focus on accelerating execution and improving its commercial results.

Industry Advisory Group

During the period, the Company also established a new Industry Advisory Group. The Group, chaired by Vitura's independent non-executive director Gerard Fogarty AO, provides expertise-based guidance to the Board, further strengthening the Company's clinical governance and improving patient experiences.

Its areas of focus include medical practice management, doctor recruitment, engagement and retention and emerging opportunities and risks across both medicinal cannabis and specialty clinics.

Comments from Vitura Chair, Robert Iervasi

"The major foundations of our Strategic Reset are in place and it's important that we now accelerate Vitura's operational and financial performance.

"While our strategic priorities haven't changed, we felt that new leadership was required to increase the focus on our key commercial objectives and drive improved shareholder value.

"While we were pleased to see an 8% lift in revenue in the first half, it's time to more fully unlock Vitura's potential across both our product and clinic operations to deliver improved bottom line performance. This will further our position as a trusted leader in digital health which delivers optimal health and wellbeing outcomes for our patients."

Dividends

No dividends were declared or paid in respect of the half-year ended 31 December 2025.

Investor Webinar

Vitura is hosting an investor webinar at **9.00am** Australian Eastern Summer Time on **Thursday, 26 February 2026**, hosted by Chair Robert Iervasi.

Registration is available via: <https://loghic.eventsair.com/211741/621401/Site/Register>

**** ENDS ****

Authorised by

Authorised for release to the ASX by the Board of Vitura Health Limited.

Contact

Vitura Health Limited

Robert Iervasi

Chair

1300 799 491

info@vitura.com.au

Media enquiries

Dieter Lehmann

Nominis Communications

+61 427 672 995

dieter@nominis.me

About Vitura Health Limited (ASX: VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.candor.com.au
The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.
- www.releaf.com.au
The Company owns a 50% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement